ArticleActa oncologica (Stockholm, Sweden)2025

Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol.

Jakob N Henriksen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.